Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
TSMC Profit Set to Surge 65% as AI Chip Demand Drives Record Earnings 
Trump Secures Russian Diesel Deal as US Fuel Prices Surge 
Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
Ethereum Foundation-Linked Wallets Move $11.13M in ETH to Kraken 
South Korea Blocks 27 Crypto Exchange Websites in Regulatory Crackdown 
UK Finance Minister Healey Calls for Fiscal Discipline Amid Global Risks 
Oil Prices Fall as Trump Ceasefire Claim Shifts Market Focus to U.S. CPI 
Bumble Shares Surge 50% on $1 Billion Buyout Talks 
Fed's Hammack Urges Faster Rate Hikes to Fight Inflation 
Moonshot AI Executives Seek Settlement Ahead of Hong Kong IPO 
Gold Prices Rebound as Dollar Weakens Ahead of US Inflation Data 
Nasdaq Faces Pullback to 26,225 Despite Bullish Outlook, UBS Says 
European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
Trump Defends Russian Diesel Deal Amid US Sanctions Backlash 
S&P 500 Rally Masks Losses for Over 40% of Stocks in 2026 
US Dollar Near 18-Month High Ahead of Inflation Data 
Add as a preferred source on Google
Samsung Biologics Co. is adding a new plant to its portfolio, and it will be its fifth facility for Contract Development and Manufacturing Organization (CDMO) deals. The South Korean biotech firm is building its newest plant in Songdo, Incheon, where it is currently headquartered.
According to The Korea Economic Daily, once Samsung Biologics completes the construction of the CDMO factory, its total production capacity will increase to 800,000 liters per year. The company is investing KRW1 trillion or $762.2 million for this project in South Korea.
It was noted that the company is making a fast follow-up with its investment since the fourth plant is also under construction. This factory has been dubbed the largest single biomanufacturing facility in the world, and construction is currently in full swing.
Samsung Group’s biotech arm confirmed the construction of its new Songdo plant late last week during its board meeting. It will soon rise on the second bio campus in the region’s free economic zone located west of Seoul. Prior to this announcement, Samsung Biologics already said in July of last year that it would allot KRW7.5 trillion to set up the campus by the year 2032.
In any case, the fifth plant will be the first one to be constructed on the second bio campus. While the third plant was built with just a KRW850 trillion budget, it is said to have a similar production capacity as the fifth factory. Sources said that the latest facility costs more because it will be constructed on a greenfield.
Korea Joongang Daily reported that Samsung Biologics would break ground for its fifth plant soon, and it is expected to be completed by September 2025. It will sit on a 96,000 square meter lot inside the Bio Campus II.
The company is expanding to take advantage of the current steady growth in demand for medical treatments. Finally, Samsung Biologics is taking this aggressive step of further building up its production facilities to cement its leadership in the global CDMO market.
“Amid the steady global demands for biopharmaceuticals, outsourcing of biomedical products is on the rise since the Covid-19 outbreak,” John Rim, Samsung Biologics’ chief executive officer, commented. “Preemptive investment is needed in order to continue our leadership in the market after the fourth plant.”
